Oncology & Cancer

Nexavar approval expanded for common thyroid cancer

(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.

Oncology & Cancer

Rare leukaemia survival-rate breakthrough

A pioneering genetic study means that children with a rare subtype of leukaemia have 75% less chance of their leukaemia recurring.

page 20 from 28